Skip to main content
Equibles
TGTX logo

TGTX · Tg Therapeutics, Inc. · Metrics

Track TGTX — free

Use TGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$61.25 +3.17 (+5.46%) Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$9.34B
Shares
153.07M
Volume · Oct 30 2.84M Avg daily vol (3M) 1.88M

TGTX metrics

108 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$58.08
Market cap
$9.34B

Price action

20 metrics
Price change (1W)
+9.3%
Price change (30D)
+4.1%
Price change (3M)
+8.5%
Price change (6M)
+71.9%
Price change (YTD)
+94.8%
Price change (1Y)
+71.9%
Trailing year
Price change (5Y)
+86.0%
52-week high
$59.06
52-week low
$26.94
Change from 52-week high
-1.7%
Change from 52-week low
+115.6%
Annualized volatility
45.6%
Annualized volatility (3M)
43.2%
Beta
0.5
RSI (14D)
62.2
Price vs SMA 50
+5.4%
Price vs SMA 200
+33.1%
Avg volume (3M)
1.88M
Relative volume
1.0
Average dollar volume
$100.53M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
153.07M

Valuation

12 metrics
P / E (TTM)
21.2
Trailing earnings · reciprocal yield 4.7%
PEG ratio
—
EV / revenue
11.3×
reciprocal yield 8.9%
EV / EBITDA
66.1×
reciprocal yield 1.5%
EV / EBIT
66.2×
reciprocal yield 1.5%
P / sales
11.0×
reciprocal yield 9.1%
P / book
14.6
reciprocal yield 6.8%
FCF yield
0.2%
TTM · current market cap
Buyback yield
0.0%
P / FCF
507.9
reciprocal yield 0.2%
P / operating cash flow
493.9
reciprocal yield 0.2%
Earnings yield
5.0%

Historical valuation

8 metrics
P / E historical average (3Y)
43.5×
reciprocal yield 2.3%
P / E historical average (5Y)
43.5×
reciprocal yield 2.3%
EV / revenue historical average (3Y)
127.8×
reciprocal yield 0.8%
EV / revenue historical average (5Y)
354.8×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
66.3×
reciprocal yield 1.5%
EV / EBIT historical average (5Y)
66.3×
reciprocal yield 1.5%
EV / EBITDA historical average (3Y)
53.2×
reciprocal yield 1.9%
EV / EBITDA historical average (5Y)
53.2×
reciprocal yield 1.9%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
82.4%
Operating margin
17.1%
Trailing 12 months
Net margin
55.2%
Gross profit (TTM)
$658.60M
Operating profit (TTM)
$136.33M
Net income (TTM)
$441.49M
Trailing 12 months
Diluted EPS (TTM)
$2.74
FCF margin
2.2%
Effective tax rate
-334.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$5.02
Gross profit per diluted share (TTM)
$4.14
Operating profit per diluted share (TTM)
$0.85
EBITDA per diluted share (TTM)
$0.86
Net income per diluted share (TTM)
$2.75
Operating cash flow per diluted share (TTM)
$0.12
Free cash flow per diluted share (TTM)
$0.11
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.42
Stock compensation per diluted share (TTM)
$0.51
Book value per share
$4.17

Growth

11 metrics
Revenue growth YoY
+70.3%
Year over year
Net income growth YoY
-72.4%
Revenue (TTM)
$799.54M
Trailing 12 months
EPS growth YoY
-70.6%
Shares change YoY
-3.2%
Year over year · fewer shares
Revenue CAGR (3Y)
+504.9%
Revenue CAGR (5Y)
+426.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
73.1%
Return on assets
26.9%
Debt / equity
1.2
Current ratio
4.3
EBITDA (TTM)
$136.45M
Free cash flow (TTM)
$17.39M
Quick ratio
3.7
Interest coverage
3.6
Net debt / EBITDA
1.4
Return on invested capital
—
Trailing 12 months
Net cash
−$193.14M
Latest balance sheet
Cash & equivalents
$482.57M
Total assets
$1.64B
Total debt
$745.39M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$17.88M
Capital expenditures (TTM)
$491,000
R&D (TTM)
$225.80M
SG&A (TTM)
$296.46M
Stock compensation (TTM)
$81.16M
R&D / revenue
28.2%
Stock compensation / revenue
10.2%

Ownership (13F)

9 metrics
13F filers
440
13F filer change QoQ
+70
Institutional ownership
75.3%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
18.6%
Private-fund adviser ownership
12.6%
Active holders' share change QoQ
+12.8%
Holder tenure
13.6
Price vs estimated holder cost
+79.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
26.7%

Short interest

3 metrics
Short interest
19.3%
Latest settlement · 18.9 days to cover
Days to cover
18.9d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$274,800
Insider-sentiment score
49 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 134 filings 122 filers Visit website Investor relations